Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Doccole on Dec 27, 2020 5:33pm

News

Are we expecting any news this week? Or after the new year will stuff start rolling in?

I imagine there is no motivation to get the stock price up when Ceo Dan and the good doc is negotiating a deal with Antibe Holdings (IP).  Correct me if I'm wrong?!
Comment by Pragmatist on Dec 27, 2020 6:37pm
  The CEO stated during Biopub that he will be submitting the IND shortly after Christmas.  I guess it depends on one's definition of "shortly".  If nothing else, this will get OTEN into the FDA system such that more meanigful discussions can begin.   Since Legault/Wallace are the majority SHs of both ATE and AHI, there clearly is a conflict of interest ...more  
Comment by MrMugsy on Dec 27, 2020 7:08pm
Well said Pragmatist ! i will add that The Board also needs to negotiate on the value of the supplemental patent.  I’m sure more information is coming as we need to know what we’re buying and Dan/Wallace are going to want to demonstrate value for this additional IP.  There certainly is a win-win opportunity here as well. Man, the next three months are so busy !!!!
Comment by Pragmatist on Dec 27, 2020 7:43pm
I agree.  In fact, the supplemental patent and all IP developed since the incorporation of ATE might very well be the underlying reason for coming to an arrangemnt. As new products/IP  come into play, accruable to ATE, the distinction between  what IP can be attributed to each party becomes increasingly blurred.  This could impact the royalty payments to AHI for new drugs ...more  
Comment by Doccole on Dec 27, 2020 7:44pm
Agreed, well said!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities